Astellas Pharma ADR Representing 1
Stock
Stock
ISIN: US04623U1025
Ticker: ALPMY
US04623U1025
ALPMY
Price
Price
CHART BY
Frequently asked questions
What is Astellas Pharma ADR Representing 1's market capitalization?
The market capitalization of Astellas Pharma ADR Representing 1 is $126.51M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Astellas Pharma ADR Representing 1's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Astellas Pharma ADR Representing 1 is 54.03. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Astellas Pharma ADR Representing 1?
Astellas Pharma ADR Representing 1's Earnings Per Share (EPS) over the trailing twelve months (TTM) is 0.001306. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Astellas Pharma ADR Representing 1's stock?
Currently, 12 analysts cover Astellas Pharma ADR Representing 1's stock, with a consensus target price of $0.0801. Analyst ratings provide insights into the stock's expected performance.
What is Astellas Pharma ADR Representing 1's revenue over the trailing twelve months?
Over the trailing twelve months, Astellas Pharma ADR Representing 1 reported a revenue of $88.25M.
What is the EBITDA for Astellas Pharma ADR Representing 1?
Astellas Pharma ADR Representing 1's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $21.00M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Astellas Pharma ADR Representing 1?
Astellas Pharma ADR Representing 1 has a free cash flow of $7.57M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Financials
- Market Cap
- $126.51M
- EPS (TTM)
- 0.001306
- P/E ratio (TTM)
- 54.03
- Revenue (TTM)
- $88.25M
- EBITDA (TTM)
- $21.00M
- Free Cashflow (TTM)
- $7.57M
Analyst Ratings
The price target is $0.0801 and the stock is covered by 12 analysts.
Buy
4
Hold
7
Sell
1
Information
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products: XTANDI, PADCEV, XOSPATA, VYLOY, VEOZAH, IZERVAY, EVRENZO, BETANIS and PROGRAF. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US04623U1025
- Primary Ticker
- ALPMY
Knockouts
LSX Data · Fundamentals & EOD data from FactSet